Terms ending in 2041
Every in-force patent on Genmab A/S's record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,570,751 | Binding Agents Binding to PD-L1 and CD137 and Use Thereof In force · Medium confidence | Genmab A/S | In force | Medium confidence | |
| US 12,324,841 | Methods of Treating Cancer with a Combination of an ANTI-PD-1 Antibody and an Anti-Tissue Factor Antibody-Drug Conjugate In force · High confidence | MSD International GmbH | In force | High confidence | |
| US 12,415,859 | Methods of Producing Heterodimeric Antibodies In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,261,254 | Antibodies In force · High confidence | Genmab A/S | In force | High confidence | |
| US 12,435,154 | Bispecific Antibodies Against CD3 and CD20 In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,535,679 | Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Follicular Lymphoma In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,548,952 | Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Diffuse Large B-Cell Lymphoma In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,608,383 | Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Follicular Lymphoma In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,845,805 | Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Diffuse Large B-Cell Lymphoma In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,858,995 | Bispecific Antibodies Against CD3 and CD20 for Treating Chronic Lymphocytic Leukemia In force · High confidence | Genmab A/S | In force | High confidence | |
| 1 more term end in 2041 · Pro | |||||
10 of 11 patents shown. Soonest term end first, then patent number.
Pro members see all 11.
10 of these are in force and held by Genmab A/S.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.